Cambrex Corp (CBM) Files Form 4 Insider Selling : William B Korb Sells 3,420 Shares

Cambrex Corp (CBM): William B Korb , director of Cambrex Corp sold 3,420 shares on Jul 11, 2016. The Insider selling transaction was reported by the company on Jul 11, 2016 to the Securities and Exchange Commission. The shares were sold at $55.00 per share for a total value of $188,100.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 10, 2016, William B Korb (director) sold 4,142 shares at $52.47 per share price.On May 10, 2016, Steven M Klosk (President & CEO) sold 14,005 shares at $49.00 per share price.Also, On Mar 16, 2016, Louis J. Grabowsky (director) purchased 750 shares at $40.10 per share price.On Mar 11, 2016, Gregory Sargen (Executive Vice President & CFO) sold 26,697 shares at $41.37 per share price.

Cambrex Corporation: On Friday, Jul 8, 2016 heightened volatility was witnessed in Cambrex Corporation which led to swings in the share price. The shares opened for trading at $53.71 and hit $54.44 on the upside , eventually ending the session at $54.16, with a gain of 1.94% or 1.03 points. The heightened volatility saw the trading volume jump to 2,90,051 shares. The 52-week high of the share price is $55.6 and the company has a market cap of $1,732 M . The 52-week low of the share price is at $29.5.

Cambrex Corporation Money Flow Index Chart

Cambrex Corporation (Cambrex) is a life sciences company that provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services worldwide to innovator and generic pharmaceutical companies. The Company’s customers include generic drug companies and companies that discover and commercialize small molecule human therapeutics using organic chemistry. Its business consists of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The Company’s products include active pharmaceutical ingredients (APIs) pharmaceutical intermediates and to a lesser extent other fine chemicals. Cambrex has three operating segments which are manufacturing facilities that have been aggregated as one reportable segment.

Leave a Reply

Cambrex Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Cambrex Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.